Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2-GDNF gene therapy in Multiple System Atrophy
NCT04680065Phase 1Active, not recruiting
- Sponsor
- Brain Neurotherapy Bio
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMT-140 in multiple system atrophy (MSA) (2 arms), sponsored by Brain Neurotherapy Bio. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events at 3 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
AMT-140
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04680065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680065.